Recognify’s RL-007 program looked stalled after its last trial, but AmyriAD Therapeutics is moving in. The Dutch biotech has snapped up Recognify Life Sciences, taking over the RL-007 asset and betting it can steer the troubled project through a crowded, unforgiving field.
This all-share acquisition hands AmyriAD full control of Recognify and inidascamine (RL-007). The companies kept financial terms under wraps. Recognify’s previous backers—atai Life Sciences, Catalio Capital Management, and Sudhoff Family Office—now hold stakes in AmyriAD. The official press release confirms Recognify is now a wholly owned subsidiary, with AmyriAD taking over both funding and development.
RL-007 demonstrated a favorable safety profile in Phase IIb, with no evidence of sedation, weight gain, or extrapyramidal symptoms reported during the trial.
RL-007’s Clinical Hurdles and AmyriAD’s Strategy
RL-007, an oral small molecule, has been tested in about 500 people and targets cholinergic and glutamatergic pathways. Recognify’s Phase IIb trial (NCT05686239) enrolled 242 patients with CIAS. The study failed to hit its main efficacy goal—the MCCB composite neurocognitive score at week 6—against placebo. AmyriAD confirmed the miss. Still, the data showed numerical gains in Symbol Coding and Speed of Processing, plus a bump in Verbal Learning. Functional capacity also trended positive. AmyriAD plans to chase these signals.
The company is pressing ahead with a pharmacokinetic study already underway, aiming for results in the first half of 2027. After that, AmyriAD will push a reformulated RL-007 and a tighter trial design, zeroing in on the cognitive areas that showed the most promise. Plans are also in motion for a Phase II study of RL-007 in mild-to-moderate Alzheimer’s disease, targeting 2027 or 2028. AmyriAD will use its existing infrastructure and regulatory know-how from its lead Alzheimer’s candidate, ismidenon (AD-101), which is set for a Phase IIb launch in 2027.
AmyriAD stated it will continue the pharmacokinetic study initiated by Recognify, with results anticipated in the first half of 2027. The company emphasized that future development will be guided by data on drug exposure and tolerability.
Competitive Landscape and Unmet Need
CIAS remains a tough target. No US FDA-approved drugs address cognitive impairment in schizophrenia. Neurocrine Biosciences recently pulled the plug on its DAAO inhibitor luvadaxistat after a second Phase II flop in 2024. The field is littered with failed attempts, but the need for effective therapies is still wide open.
Biotechs are increasingly willing to take a second shot at assets with mixed or negative data, as long as there’s a hint of efficacy in secondary endpoints. AmyriAD’s move fits this pattern. The approach mirrors risk-taking seen in other advanced therapy areas, like the push for room-temperature cell therapy storage covered by CityBiz.
AmyriAD is betting that a sharper trial design and a focus on the strongest cognitive signals can deliver where others have failed. The company’s takeover of Recognify and RL-007 puts it on the hook for the next round of data, with the next major readout expected in 2027.
